Location: MAPLE GROVE, MN
About this partner
Laplace Interventional’s device offers an increase in life expectancy and quality of life to the 500K+ patients in the US and EU diagnosed with tricuspid regurgitation (TR) every year. TR occurs when the tricuspid valve leaks resulting in right side heart failure. Despite severe to moderate TR leading to a high mortality rate (>50% at four years), more than 90% of these 500K+ patients go untreated. Laplace Interventional’s artificial valve is delivered through a simple, minimally invasive procedure, reducing future complications in patients. Laplace Interventional’s founder developed this patent-pending transcatheter device utilizing his 10+ years of heart valve development experience and knowledge.
Laplace Interventional Inc. Announces $7.9M Series A for its Transcatheter Tricuspid Valve Technology
In The Know: Healthcare News for May 31, 2021
In The Know: Healthcare News for March 15, 2021